NCT06491576

A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis

A Single-center, Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled Phase Ib/IIa Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of BGT-002 Tablets in Subjects With NASH

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Burgeon Therapeutics Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is a single-center, randomized, double-blind, multiple ascending doses (MAD), placebo-controlled phase Ib/IIa clinical trial of BGT-002 Tablets in subjects with NASH to evaluate the safety, tolerability, pharmacokinetics (PK) and early pharmacodynamics (PD) of BGT-002 Tablets.

Conditions

• NASH

Interventions

Type	Name	Description
DRUG	BGT-002	taking the study drug orally
DRUG	Placebo	taking the placebo orally

Timeline

• Start date: 2023-03-21
• Primary completion: 2024-03-04
• Completion: 2024-03-04
• First posted: 2024-07-09
• Last updated: 2024-07-09

Locations

1 site across 1 country: China